Intact Investment Management Inc. Sells 76,100 Shares of Bausch Health Cos Inc. (NYSE:BHC)

Intact Investment Management Inc. lessened its stake in Bausch Health Cos Inc. (NYSE:BHC - Free Report) by 29.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 185,200 shares of the company's stock after selling 76,100 shares during the quarter. Intact Investment Management Inc. owned 0.05% of Bausch Health Cos worth $1,201,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently modified their holdings of the company. JPMorgan Chase & Co. raised its position in shares of Bausch Health Cos by 1,246.0% in the 4th quarter. JPMorgan Chase & Co. now owns 19,840 shares of the company's stock worth $160,000 after purchasing an additional 18,366 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Bausch Health Cos by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 11,684,859 shares of the company's stock worth $94,460,000 after purchasing an additional 145,078 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Bausch Health Cos in the 4th quarter worth about $180,000. Two Sigma Investments LP raised its position in shares of Bausch Health Cos by 688.2% in the 4th quarter. Two Sigma Investments LP now owns 265,461 shares of the company's stock worth $2,140,000 after purchasing an additional 231,781 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Bausch Health Cos by 1.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,284,036 shares of the company's stock worth $10,375,000 after purchasing an additional 14,558 shares during the last quarter. Hedge funds and other institutional investors own 78.65% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Wall Street Zen lowered Bausch Health Cos from a "buy" rating to a "hold" rating in a research report on Saturday, May 10th. Royal Bank Of Canada lifted their price target on Bausch Health Cos from $8.50 to $10.00 and gave the stock a "sector perform" rating in a research report on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating and seven have assigned a hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $7.42.

Insider Buying and Selling

In other Bausch Health Cos news, Director John Paulson acquired 3,564,059 shares of Bausch Health Cos stock in a transaction that occurred on Friday, June 13th. The stock was bought at an average cost of $5.94 per share, for a total transaction of $21,170,510.46. Following the acquisition, the director now owns 32,791,702 shares of the company's stock, valued at $194,782,709.88. This represents a 12.19% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders acquired 6,352,667 shares of company stock worth $35,870,767. 8.12% of the stock is owned by corporate insiders.

Bausch Health Cos Price Performance

NYSE BHC traded down $0.07 during trading hours on Monday, hitting $6.11. The company's stock had a trading volume of 2,304,824 shares, compared to its average volume of 2,623,766. Bausch Health Cos Inc. has a 12 month low of $3.96 and a 12 month high of $9.85. The company's 50 day simple moving average is $5.02 and its two-hundred day simple moving average is $6.32. The company has a market cap of $2.26 billion, a P/E ratio of -55.55 and a beta of 0.28.

Bausch Health Cos Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.